Laboratorio Clinico Y Bacteriologico Licer

Summary Statement of Deficiencies D0000 The Centers for Medicare & Medicaid Services (CMS) conducted an unannounced CLIA recertification survey at Laboratorio Clinico Y Bacteriologico Licer on May 7, 2026. The laboratory was surveyed under 42 CFR part 493 CLIA requirements. The following standard level deficiencies were found during the recertification CLIA survey ending on May 7, 2026. D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) (d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on observation, quality control records review, and laboratory director interview on May 7, 2026 at 9:38 AM, the laboratory used the wright stain reagent kit with exceeded expiration date, on 38 peripheral smear patient tests from July 7, 2024 to May 7, 2026. The findings include: 1. The laboratory uses Camco Quik Stain II Wright- giemsa stain reagent kit to perform hematology peripheral smear tests. 2. Observation of the laboratory wright stain reagent kit on May 7, 2026 at 9:38 AM, showed that wright stain reagent in use exceeded the expiration date, lot # 1029, expiration date July 6, 2024. 3. Wright stain hematology quality control records review on May 7, 2026 at 9:38 AM, showed that the laboratory used the wright stain reagent kit with exceeded expiration date, when the laboratory processed and reported 38 peripheral smear patient tests from July 7, 2024 to May 7, 2026. 4. The laboratory director confirmed on May 7, 2026 at 9:45 AM, that the laboratory used wright stain reagent kit with exceeded expiration, when the laboratory processed and reported 38 peripheral smear patient tests from July 7, 2024 to May, 7, 2026. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- D5429 MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(a)(1) (a)(1) Maintenance as defined by the manufacturer and with at least the frequency specified by the manufacturer. This STANDARD is not met as evidenced by: Based on lack of Cobas e411 maintenance quality control records, manufacturer's instructions, and laboratory director interview on May 7, 2026 at 2:32 PM, the laboratory failed to perform the following instrument maintenance: daily, weekly, every two weeks and as needed instrument maintenance, when they processed and reported 10, 876 patient samples from January 1, 2025 to May 7, 2026 for special chemistry tests. The findings include: 1. The laboratory uses the Cobas e411 instrument to perform special chemistry tests. 2. Review of the Cobas e411 instrument manufacturer's instructions on May 7, 2026 at 2:26 PM, showed that the instrument maintenance includes the following: daily: clean sample reagent probe, check condensation inside compartments, check water level, empty liquid and solid waste, weekly: clean sipper probe, and incubator and aspiration station, every two weeks: clean rinse station, perform liquid flow cleaning, as needed: perform finalization maintenance, clean: system water container, liquid waste container, microbead mixer, ProCell & CleanCell compartments, reagent rotor & compartments, reagent compartment, and perform empty solid waste tray and protect the measuring cell. 3. On May 7, 2026 at 2:32 PM, the Cobas e411 instrument maintenance quality control records were requested. The laboratory did not have instrument maintenance records since January 1, 2025 to May 7, 2026, when they processed and reported 10, 876 patient specimens for special chemistry tests. 4. The laboratory director confirmed on May 7, 2026 at 2:39 PM, that the laboratory did not perform the instrument maintenance of the special chemistry instrument from January 1, 2025 to May 7, 2026, when they processed and reported 10, 876 patient samples. D5547 HEMATOLOGY CFR(s): 493.1269(c)(d) (c) For manual coagulation tests-- (c)(1) Each individual performing tests must test two levels of control materials before testing patient samples and each time a reagent is changed; and (c)(2) Patient specimens and control materials must be tested in duplicate. (d) The laboratory must document all control procedures performed, as specified in this section. This STANDARD is not met as evidenced by: Based on observation, hematology wright stain quality control records review, and interview with the laboratory director on May 7, 2026 at 9:30 AM, the laboratory did not document the kit, lot and expiration date of the wright stain reagent. The findings include: 1. The laboratory uses Camco Quik Stain II Wright- giemsa stain reagent to perform hematology peripheral smear tests. 2. On May 7, 2026 at 9:30 AM, the hematology wright stain quality control records, showed that the laboratory did not document the following information: kit, lot and expiration date from July 7, 2024 to May 7, 2026, when they processed and reported 38 hematology peripheral smear patient's staining results. 3. The laboratory director confirmed at 9:35 AM that the laboratory failed to document the kit, lot and expiration date from the hematology stain kit that was in use from July 7, 2024 to May 7, 2026. -- 2 of 3 -- D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) (e)(5) Ensure that the quality control and quality assessment programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur; This STANDARD is not met as evidenced by: Based on hematology and chemistry observation, quality control records, manufacturer's instructions, and interview with the laboratory director on May 7, 2026 at 2:39 PM, the laboratory director failed to fulfill her responsibilities and duties to ensure compliance with the hematology and chemistry quality control requirements. Refer to D5417, D5429, and 5547. D6177 TESTING PERSONNEL RESPONSIBILITIES CFR(s): 493.1495(b)(3) (b)(3) Adhere to the laboratorys quality control policies, document all quality control activities, instrument and procedural calibrations and maintenance performed; This STANDARD is not met as evidenced by: Based on hematology and chemistry observation, quality control records, manufacturer's instructions, and interview with the laboratory director on May 7, 2026 at 2:39 PM, the laboratory testing personnel failed to perform and document all quality control activities to ensure compliance with the hematology and chemistry quality control requirements. Refer to D5417, D5429, and 5547. -- 3 of 3 --

Summary Statement of Deficiencies D2000 ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801 Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994. This CONDITION is not met as evidenced by: Based on lack of proficiency testing record, bacteriology patient records review and laboratory director interview, it was determined that the laboratory failed to enroll in an Human Health Services (HHS) approved Proficiency Testing Program for the following bacteriology tests results: urine Growth or No Growth cultures tests (Non- waived method) 1,969 out of 1,969 patients urine cultures were processed and reported from January 3, 2021 to April 18, 2022. The findings include: 1. On April 19, 2022 at 9:38 AM, the laboratory did not have records of Proficiency testing results for the following bacteriology tests results: urine Growth or No Growth cultures tests (Non-waived method) from January 3, 2021 to April 18, 2022. 2. The laboratory director confirmed on April 19, 2021 at 9:52 AM, that the laboratory did not enroll nor participate in an HHS approved Proficiency Testing Program for those tests since January 3, 2021. She stated that the laboratory establishes a comparison protocol to verify twice a year those tests. 3. The laboratory processed and reported 1,969 out of 1,969 patients urine cultures patients specimens for urine growth or no growth cultures tests from January 3, 2021 to April 19, 2022. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 5 -- D5403 PROCEDURE MANUAL CFR(s): 493.1251(b) The procedure manual must include the following when applicable to the test procedure: (1) Requirements for patient preparation; specimen collection, labeling, storage, preservation, transportation, processing, and referral; and criteria for specimen acceptability and rejection as described in 493.1242. (2) Microscopic examination, including the detection of inadequately prepared slides. (3) Step-by-step performance of the procedure, including test calculations and interpretation of results. (4) Preparation of slides, solutions, calibrators, controls, reagents, stains, and other materials used in testing. (5) Calibration and calibration verification procedures. (6) The reportable range for test results for the test system as established or verified in 493.1253. (7) Control procedures. (8)

Summary Statement of Deficiencies D2000 ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801 Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994. This CONDITION is not met as evidenced by: Based on lack of Proficiency testing record for bacteriology tests, bacteriology testing records review and laboratory technical supervisor interview on April 5, 2018 at 9:10 AM, it was determined that the laboratory failed to enroll in an HHS approved Proficiency Testing Program for Bacteriology growth or no growth organisms results when it processed 4009 out of 4009 patients cultures specimens cultures from January 2016 to April 4, 2018. The findings include: 1. The Proficiency testing showed no records for bacteriology tests from January 2016 to April 4, 2018. 2. On April 5, 2018 at 9:10 AM, the bacteriology testing record showed that the laboratory performed the primary inoculation in patients cultures specimens since January 2016. During years 2016 processed nasal, throat and urine cultures, during year 2017 processed urine cultures and in the current year 2018 processed nasal, throat and urine cultures. The laboratory reported no growth and colony count results and referred cultures to another laboratory for organisms identification and susceptibility tests. 3. The technical supervisor confirmed on April 5, 2018 at 9:20 AM, that the laboratory performed the primary inoculation for the patients cultures specimens, reported no growth and colony count results and referred cultures to another laboratory for Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- organisms identification and susceptibility tests since January 2016. She also confirmed that the laboratory did not enroll and participate in an HHS approved Proficiency Testing Program for those tests; instead the laboratory performed a comparison procedures since April 2016. 3. The laboratory performed the primary inoculation for the following patients cultures specimens from January 2016 to April 4, 2018: a. 2,502 patients cultures specimens during year 2016. b. 1,126 patients cultures specimens during year 2017. c. 381 patients cultures specimens for the current year 2018. D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on personnel records review and laboratory technical supervisor interview on April 5, 2018 at 8:30 AM, it was determined that the laboratory failed to follow the established schedule for the technical supervisor competence evaluation. The findings include: a. The laboratory schedule for the technical supervisor competence evaluation showed that it must be performed every year. b. The laboratory did not perform the technical supervisor competence evaluations since February 2017. D5291 GENERAL LABORATORY SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1239(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and, when indicated, correct problems identified in the general laboratory systems requirements specified at 493.1231 through 493.1236. This STANDARD is not met as evidenced by: Based on Quality Assessment (QA) records review, personnel records review and laboratory technical supervisor interview on April 5, 2018 at 8:30 AM, it was determined that laboratory failed to follow the established Quality Assessment Program to monitor and evaluate yearly the requirements for the technical supervisor competence. Refer to D 5209. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. -- 2 of 4 -- This STANDARD is not met as evidenced by: Based on review of validation records of the Mindray system for complete cell count (CBC) test and technical supervisor interview on April 5, 2018 at 9:28 AM, it was determined that the laboratory failed to complete the evaluation of the performance specifications of this new instruments on April 27, 2017 before reporting 2861 out of 2861 CBC tests results from October 2017 to April 4, 2018. The findings include: 1. On April 5, 2018 at 9:28 AM, the Mindray system validation records showed that the laboratory laboratory performed the validation procedures on April 27, 2017 and it did not verify that the manufacturer's CBC reference intervals (normal values) are appropriate for the laboratory's patient population. 2. The technical supervisor confirmed on April 5, 2018 at 9:38 AM, that the laboratory did not verify that the Mindray system manufacturer's reference intervals (normal values) when it validated the system on on April 27, 2017. She stated that the laboratory processed and reported the CBC patients specimens by the Mindray system since October 13, 2017 and the laboratory included in the Mindray system CBC reports the reference intervals of the former laboratory CBC tests analyzer ( Excell 2280 system). 4. The laboratory processed and reported 2861 out of 2861 CBC patients specimens by the Mindray system from October 2017 to April 4, 2018: 198 CBC in October 2017, 361 CBC in November 2017, 385 CBC in December 2017, 728 in January 2018, 476 CBC in February 2018, 630 CBC in March 2018 and 83 CBC from April 1 to April 4, 2018. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on lack of Proficiency testing record for bacteriology tests, bacteriology testing records review, review of validation records of the Mindray system for complete cell count (CBC) test and technical supervisor interview on April 5, 2018 at 9:28 AM, it was determined that the laboratory director failed to fulfill her responsibilities and duties to ensure compliance with the Proficncy Testing Program for bacteriology requirements and with the analytical system requirements for the CBC tests. The findings include: 1. The laboratory director did not comply with the Proficncy Testing Ptogram for bacteriology. Refer to D 6088. 2. The laboratory director did not comply with the analytical systems requirements for CBC tests. Refer to D 6093. D6088 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(4) The laboratory director must ensure that the laboratory is enrolled in an HHS- approved proficiency testing program for the testing performed. This STANDARD is not met as evidenced by: Based on lack of Proficiency testing record for bacteriology tests, bacteriology testing records review and laboratory technical supervisor interview on April 5, 2018 at 9:10 AM, it was determined that the laboratory director failed to ensure that the laboratory is enrolled in an HHS-approved proficiency testing program for Bacteriology growth or no growth organisms results when it processed 4009 out of 4009 patients cultures -- 3 of 4 -- specimens cultures from January 2016 to April 4, 2018. The finding includes: 1. The laboratory processed and reported patients cultures specimens for growth or no growth and colony count results from January 2016 to April 4, 2018. However, the laboratory is not enroll in a an HHS-approved proficiency testing program for those tests. Refer to D 2000. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on review of validation records of the Mindray system for complete cell count (CBC) test and technical supervisor interview on April 5, 2018 at 9:28 AM, it was found that the laboratory director failed to ensure compliance with the analytic system requirements for the CBC tests when the laboratory processed and reported 2861 out of 2861 CBC tests by the Mindray system results from October 2017 to April 4, 2018. The finding includes: 1. The laboratory director failed to ensure compliance with the analytic system requirements of the CBC tests from October 2017 to April 4, 2018. Refer to D 5421. ( The laboratory did not verify that the manufacturer's CBC reference intervals (normal values) are appropriate for the laboratory's patient population .follow before reporting 2861 out of 2861 CBC tests results by the Mindray system from October 2017 to April 4, 2018.) D6117 TECHNICAL SUPERVISOR RESPONSIBILITIES CFR(s): 493.1451(b)(4) The technical supervisor is responsible for establishing a quality control program appropriate for the testing performed and establishing the parameters for acceptable levels of analytic performance and ensuring that these levels are maintained throughout the entire testing process from the initial receipt of the specimen, through sample analysis and reporting of test results. This STANDARD is not met as evidenced by: Based on review of validation records of the Mindray system for complete cell count (CBC) test and technical supervisor interview on April 5, 2018 at 9:28 AM, it was determined that technical supervisor failed to ensure compliance with the requirements for analytic systems of the CBC tests from October 2017 to April 4, 2018. Refer to D 5421. ( The laboratory did not verify that the manufacturer's CBC reference intervals (normal values) are appropriate for the laboratory's patient population .follow before reporting 2861 out of 2861 CBC tests results by the Mindray system from October 2017 to April 4, 2018.) -- 4 of 4 --